Clinical trial
Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4…
NCT00325156 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00325156 |
|---|---|
| Title | Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants |
| Official title | An Open, Multicentric, Post-marketing Surveillance Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 and 18 Months of Age, in Healthy Infants. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diphtheria, Tetanus, Poliomyelitis, Acellular Pertussis, Haemophilus Influenzae Type b, Diphtheria-Tetanus-aPertussis-Poliomyelitis Vaccines |
| Intervention type | Biological |
| Interventions | GSK Biologicals' combined DTPa-IPV/Hib vaccine |
| Enrollment | 2,590 |
| Start date | Nov 2, 2004 |
| Primary completion | Aug 23, 2007 |
| Completion | Aug 23, 2007 |
| First posted | May 12, 2006 |
| Last update posted | Jan 2, 2020 |
| Countries | Singapore |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: